@article {8205,
	title = {2chlorodeoxyadenosine therapy of patients with Waldenstr{\"o}m macroglobulinemia previously treated with fludarabine},
	journal = {Annals of Oncology},
	volume = {5},
	year = {1994},
	note = {Cited By :39Export Date: 21 February 2017},
	month = {1994},
	pages = {288 - 289},
	abstract = {Background: Fludarabine monophosphate and 2Chlorodeoxyadenosine are nucleoside analogues with activity against Waldenstr{\"o}m macroglobulinemia. However, it is not clear whether prior exposure to one analogue precludes response to the other compound. Patients and methods: Fourteen patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia and prior exposure to fludarabine were treated with two courses of 2chlorodeoxyadenosine. Results: Three out of four patients that had previously responded to fludarabine and were relapsing from unmaintained remission, achieved a partial response with 2chlorodeoxyadenosine therapy. However, only one out of 10 patients with disease resistant to fludarabine responded to 2chlorodeoxyadenosine. Conclusions: 2chlorodeoxyadenosine may be effective in patients with Waldenstr{\"o}m macroglobulinemia sensitive to fludarabine. However, this compound has limited activity for patients with disease resistant to fludarabine. {\textcopyright} 1994 Kluwer Academic Publishers.},
	keywords = {2Chlorodeoxyadenosine, Fludarabine, Waldenstr{\"o}m macroglobulinemia},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028354954\&partnerID=40\&md5=20e61e0a06d69bd64ceca78d04a24c47},
	author = {Dimopoulos, M.A. and Weber, D.M. and Kantarjian, H. and Keating, M. and Alexanian, R.}
}
